Psoriasis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• IL-17 12
• IL-23 6
• STAT3 0
• TNF 5
• JAK 1
• GLP-1 5
• TYK2 1
• PI3K 0
• NLRP3 0
• IL-6 0
• IL-1 0
• AKT 0
• MAPK 0
• PDE4 1
• NRF2 0
• PD-1 0
• PPAR 0
• STING 0
• mTOR 0
• TLR4 0
• AMPK 0
• ERK 0
• GIP 1
• MMP-9 0
• PD-L1 0
• VEGF 0
• COX-2 0
• HIF-1 0
• IL-4 0
• SIRT1 0
• TP53 0
• APOE 0
• CGRP 0
• IL-13 0
• KEAP1 0
• LAG-3 0
• PCSK9 0
• PKM2 0
• SGLT2 0
• TSLP 0
• AR 0
• BCL-2 0
• BDNF 0
• BRD4 0
• CD123 0
• CD19 0
• CD40 0
• CSF1R 0
• CTLA-4 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• EZH2 0
• FTO 0
• G6PD 0
• GPRC5D 0
• HMGB1 0
• HSP90 0
• IDH 0
• JNK 0

EU-13 is a filter, not a ranking: it only narrows the list.

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  TYK2 Inhibition in Paradoxical Psoriasis

  NCT06281106· Prof Curdin Conrad· Updated 2 Apr 2025

  “External research funds were canceled, so study could unforunately not be continued”Registry text, quoted unchanged. Source

• Terminated

  VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

  NCT05715125· Ventyx Biosciences, Inc· Updated 27 Dec 2024

  “sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

  NCT05655299· Ventyx Biosciences, Inc· Updated 19 Sept 2024

  “Business Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

  NCT05730725· Bristol-Myers Squibb· Source

• Molecular effects of deucravacitinib on plaque psoriasis and hard-to-treat psoriasis sites.

  2023-508948-22-00· Charite Universitaetsmedizin Berlin KöR· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 4
• Gene Expression Profiling 66
• Sequence Analysis, RNA 6
• Exome Sequencing 5
• Proteomics 24
• Metabolomics 13
• Flow Cytometry 11
• Immunohistochemistry 24
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 23
• Machine Learning 27
• Deep Learning 4
• Cohort Studies 63
• Genome-Wide Association Study 38

• Machine learning-derived R-loop-related diagnostic signature for psoriasis: a multi-cohort and single-cell validation study.

  Front Immunol, Oct 2026

• Identification of psoriasis-associated hub genes by integrated transcriptomics and machine learning.

  Front Immunol, Oct 2026

• Construction of risk prediction models for psoriasis based on 45 dietary nutrients using machine learning and SHAP analysis.

  Asia Pac J Clin Nutr, Oct 2026

• Psoriatic arthritis digital phenotyping and inflammation drivers (PDPID) study: protocol for an international multicentre prospective cohort.

  BMJ Open, Sept 2026

• Transcriptomic characterization of key psoriasis-associated genes based on single-cell RNA-seq and machine learning.

  PLoS One, Jul 2026

• Integrated bioinformatics and machine learning for shared diagnostic genes and mechanisms between periodontitis and psoriasis.

  Clin Rheumatol, Jun 2026

• An Exploratory Transcriptomic Classification Model for Psoriasis Based on Apoptosis-Associated and Proliferation-Apoptosis-Coupled Genes Using Explainable Machine Learning.

  Int J Mol Sci, Jun 2026

• Gold-Functionalized Multilayer Heterojunction Microarchitectures Enable High-Fidelity Serum Metabolite Profiling for Skin Cancer Subtype Classification.

  Small Methods, Jun 2026

• Clinical investigation of a digital biomarker for joint swelling in inflammatory arthritis based on automated quantification of dorsal finger fold patterns.

  Sci Rep, Jun 2026

• Novel post-translational modification learning signature reveals DPP3 promotes progression of psoriasis by enhancing inflammatory activation.

  Gene, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.